# A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)

> **NCT07311551** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Bhavya Bhavya, MD** · enrollment: 112 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Dapagliflozin (10Mg Tab) along with standard medical therapy
- **DRUG:** Empagliflozin (25 Mg Tab) along with standard medical therapy

## Key facts

- **NCT ID:** NCT07311551
- **Lead sponsor:** Bhavya Bhavya, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-24
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07311551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07311551, "A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07311551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*